{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-001488","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2024-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.685853+00:00","generated_at":"2026-06-07T03:57:16.668903+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Axsome reports preliminary Q4 net product revenue of $71M; full year $204M","bullets":["Preliminary total net product revenue: $71M for Q4 2023, $204M for full year 2023.","Auvelity net sales: $49M Q4, $130M FY; Sunosi net revenue: $22M Q4, $74M FY.","2024 regulatory milestones: NDA submission for AXS-14 (fibromyalgia) Q1; NDA resubmission for AXS-07 (migraine) H1.","2024 clinical readouts: Phase 3 SYMPHONY (narcolepsy) Q1, ADVANCE-2 (Alzheimer's agitation) H1, FOCUS (ADHD) H2.","2024 trial initiations: Phase 3 solriamfetol for MDD, BED, SWD Q1; Phase 2/3 AXS-05 for smoking cessation."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-001488","json":"https://secwatch.observer/filing/0000950170-24-001488.json","markdown":"https://secwatch.observer/filing/0000950170-24-001488.md","text":"https://secwatch.observer/filing/0000950170-24-001488.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000095017024001488/0000950170-24-001488-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000095017024001488/axsm-20240104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T03:57:16.668903+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"387b8540e12a89098961473bf92b1b2985a17e27","claim":"Axsome Therapeutics, Inc. reported the full year of 2023 results: revenue $204 million.","evidence_excerpt":"Axsome expects total product revenue to be approximately $71 million and $204 million for the fourth quarter and full year of 2023, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1579428/000095017024001488/0000950170-24-001488-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year of 2023"},{"label":"Revenue","value":"$204 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"4ad9e1b3a90848ec981f79f01b5734bc96db905a","claim":"Axsome Therapeutics, Inc. reported the fourth quarter of 2023 results: revenue $71 million.","evidence_excerpt":"Axsome expects total product revenue to be approximately $71 million and $204 million for the fourth quarter and full year of 2023, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1579428/000095017024001488/0000950170-24-001488-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2023"},{"label":"Revenue","value":"$71 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}